Bristol/Gilead Joint Venture Targets 2005 Filing For HIV Fixed-Dose Combo
This article was originally published in The Pink Sheet Daily
Executive Summary
The joint venture is expected to use a new brand name for the fixed-dose combination of Sustiva and Truvada. Bristol and Gilead will receive sales revenues from the combination product “at percentages relative to the contribution represented by their individual products.”
You may also be interested in...
Bristol/Gilead HIV Combo Will Go To FDA In Mid-2006
The combination of Bristol’s Sustiva and Gilead’s Truvada would be the first complete HAART regimen available as a single once-daily tablet.
Bristol/Gilead HIV Combo Will Go To FDA In Mid-2006
The combination of Bristol’s Sustiva and Gilead’s Truvada would be the first complete HAART regimen available as a single once-daily tablet.
Bristol/Gilead Triple Combination HIV Therapy Has Back-Up
Bristol-Myers Squibb and Gilead are developing a "back-up" formulation of the fixed-dose combination of Sustiva and Truvada that is the subject of their joint venture